These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

232 related items for PubMed ID: 28485182

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Real-World Performance of Paclitaxel Drug-Eluting Bare Metal Stenting (Zilver PTX) for the Treatment of Femoropopliteal Occlusive Disease.
    Tran K, Ullery BW, Kret MR, Lee JT.
    Ann Vasc Surg; 2017 Jan; 38():90-98. PubMed ID: 27554688
    [Abstract] [Full Text] [Related]

  • 9. Bare metal stent versus paclitaxel eluting stent for intermediate length femoropopliteal arterial lesions (BATTLE trial): study protocol for a randomized controlled trial.
    Gouëffic Y, Kaladji A, Guyomarch B, Montagne C, Fairier D, Gestin S, Riche VP, Vent PA, Chaillou P, Costargent A, Patra P.
    Trials; 2014 Oct 30; 15():423. PubMed ID: 25359394
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Vessel Calcification as a Risk Factor for In-Stent Restenosis in Complex Femoropopliteal Lesions After Zilver PTX Paclitaxel-Coated Stent Placement.
    Ichihashi S, Shibata T, Fujimura N, Nagatomi S, Yamamoto H, Kyuragi R, Adachi A, Iwakoshi S, Bolstad F, Saeki K, Obayashi K, Kichikawa K.
    J Endovasc Ther; 2019 Oct 30; 26(5):613-620. PubMed ID: 31257994
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Drug-eluting stenting for femoropopliteal lesions, followed by cilostazol treatment, reduces stent restenosis in patients with symptomatic peripheral artery disease.
    Zen K, Takahara M, Iida O, Soga Y, Kawasaki D, Nanto S, Yokoi H, Matoba S, ZEPHYR Investigators.
    J Vasc Surg; 2017 Mar 30; 65(3):720-725. PubMed ID: 28073668
    [Abstract] [Full Text] [Related]

  • 19. Impact of Cilostazol Administration on Femoropopliteal In-Stent Restenosis.
    Tomoi Y, Soga Y, Iida O, Fujihara M, Ando K.
    J Endovasc Ther; 2017 Oct 30; 24(5):640-646. PubMed ID: 28675951
    [Abstract] [Full Text] [Related]

  • 20. Comparative Effectiveness Study of Drug-Eluting and Bare-Metal Peripheral Artery Stents in Endovascular Femoropopliteal Artery Revascularization.
    Jeon-Slaughter H, Khalili H, Tsai S, Armstrong EJ, Shammas NW, Jawaid O, Lu H, Addo T, Gigliotti O, Abu-Fadel M, Banerjee S.
    J Invasive Cardiol; 2018 Oct 30; 30(10):373-379. PubMed ID: 30279293
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.